Unnecessary antipsychotic medication continued without documented indication
Summary
Failure to ensure Resident #5 was free from unnecessary drugs occurred when the facility continued an antipsychotic medication without documented ongoing need. Resident #5 was admitted with multiple diagnoses including dementia with behavioral disturbance, psychotic disturbance, mood disturbance, Parkinson's disease with dyskinesia, major depressive disorder, anxiety disorder, and severe cognitive impairment as reflected by a BIMS score of 7. The resident was admitted from the hospital with an order for quetiapine/Seroquel for anxiety, and on 12/31/25 the NP ordered the medication weaned with a plan to decrease it and obtain a psych NP evaluation. A nurse progress note dated 1/6/26 documented that the NP ordered Seroquel discontinued and that the responsible party was updated, but the physician orders and MAR from 12/31/25 through 2/19/26 still showed quetiapine fumarate 25 mg at bedtime for anxiety. The medication was not discontinued as documented in the progress note. A multidisciplinary care conference on 1/7/26 included the resident and a family member who expressed a desire for psych services, but there was no review of the quetiapine order by the interdisciplinary team. On 1/24/26, the psych NP increased sertraline from 50 mg to 75 mg daily. On 2/3/26, the attending physician documented that the resident was pleasantly confused at baseline, sleeping well, and receiving sertraline 75 mg daily with quetiapine 25 mg at bedtime for MDD with mood disorder, while also noting no tearful moments, suicidal ideations, or visual or auditory hallucinations. Progress notes from the NP and physician described the resident as pleasant without confusion, agitation, depression, or anxiety. ADL behavior monitoring for January and February 2026 showed no behaviors observed, and staff interviews on 2/19/26 confirmed the resident had not exhibited agitation, aggression, nervousness, tearfulness, or anxiety. The DON stated antipsychotics should be used to treat a psychiatric diagnosis or when justified for other symptoms and that behavior monitoring, side effect monitoring, and GDRs were expected as appropriate. The consultant pharmacist had recommended behavior monitoring, adverse effect tracking, and AIMS monitoring, but the report states the consultant pharmacist recommendations were not located in the electronic record and behavior monitoring/adverse effect tracking was not found on the MAR for the antipsychotic. The facility later presented a consultant pharmacist recommendation and NP note stating the resident had no behavioral disturbances, no agitation, no mood instability, and no symptoms consistent with active generalized anxiety disorder, and that discontinuation of Seroquel was clinically appropriate.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.